Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biolog...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 February 2022
|
| In: |
Journal of law and the biosciences
Year: 2022, Jahrgang: 9, Heft: 1, Pages: 1-18 |
| ISSN: | 2053-9711 |
| DOI: | 10.1093/jlb/lsac001 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/jlb/lsac001
|
| Verfasserangaben: | Victor L. Van de Wiele, Maximilian Hammer, Ravi Parikh, William B. Feldman, Ameet Sarpatwari and Aaron S. Kesselheim |
| Zusammenfassung: | Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for this disease. Currently, treatment options include three originator biologics with approvals for neovascular AMD (aflibercept, ranibizumab, and brolucizumab-dbll) and one biologic that is commonly used off-label for the condition (bevacizumab). In the USA, Medicare spending on these drugs consistently surpassed |
|---|---|
| Beschreibung: | Gesehen am 19.05.2022 |
| Beschreibung: | Online Resource |
| ISSN: | 2053-9711 |
| DOI: | 10.1093/jlb/lsac001 |